The Origin Story of Omnipod®: Celebrating 25 Years of Innovation at Insulet

How did a sketch on a napkin during a cross-country flight spark a revolution in diabetes care? Following live discussions at the European Association for the Study of Diabetes (EASD) 2025 in Vienna, Within Range host Kate Neal introduces a special conversation led by Dominic Hulton, Vice President of International Marketing at Insulet, with John Brooks, founder of Insulet and the visionary behind tubeless insulin delivery which eventually led to the development of the Omnipod 5 Automated Insulin Delivery System.  John shares personal insights into the early days of Insulet, developing the first tubeless insulin delivery system and the impact of creating a technology that continues to empower people living with diabetes around the world. The discussion also looks ahead to the next era of innovation, exploring how advances in CGM integration, automation, and immunology could shape the future of diabetes management.  Note: The information in this podcast is accurate to the date of recording as of 09/16/2025. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.   INS-OS-10-2025-00022 v1.0